Vireo Growth (VREOF) Non-Current Deferred Tax Liability (2025 - 2026)

Vireo Growth's (VREOF) quarterly Non-Current Deferred Tax Liability came in at $8.1 million in Q1 2026, down 20.59% quarter-over-quarter from $10.2 million in Q4 2025.

Vireo Growth (VREOF) Non-Current Deferred Tax Liability (2025 - 2026) Analysis & Trends

Vireo Growth has disclosed Non-Current Deferred Tax Liability across 2 years of filings, most recently posting $8.1 million for Q1 2026.

  • Non-Current Deferred Tax Liability for Q1 2026 came in at $8.1 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $8.1 million (changed N/A YoY), and the FY2025 annual result was $10.2 million, changed N/A from the prior year.
  • Non-Current Deferred Tax Liability came in at $8.1 million for Q1 2026 at Vireo Growth, down from $10.2 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $10.2 million in Q4 2025 to a low of $8.1 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn
10 Vireo Growth - - 59.30 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 8.10 Mn
Mar 31, 2026 8.10 Mn
Dec 31, 2025 10.20 Mn
Dec 31, 2025 10.20 Mn